echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Haisco intends to sell the ownership of four related proprietary technologies including DPP1 inhibitors to a Singapore company

    Haisco intends to sell the ownership of four related proprietary technologies including DPP1 inhibitors to a Singapore company

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 5, Haisco announced that the company intends to sign a "technology transfer contract" with the company’s fourth-tier subsidiary HAISCO PHARMACEUTICALS PTE.


    Haisco stated that the company sold the proprietary technology of four projects of DPP1 inhibitor, EZH1/2 dual-target inhibitor, JAK inhibitor and Nrf2 agonist drugs in markets outside the Chinese mainland (including Hong Kong, Macau and Taiwan) to the Singapore company for the purpose of Better promote the overseas operation and development of the company's innovative drug research projects


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.